1. Baker, K. P., Edwards, B. M., Main, S. H., Choi, G. H., Wager, R. E., Halpern, W. G., Lappin, P. B., Riccobene, T., Abramian, D., Sekut, L., et al. (2003). Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum.48,3253–3265.
2. Do, R. K. G., Hatada, E., Lee, H., Tourigny, M. R., Hilbert, D., and Chen-Kiang, S. (2000). Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J. Exp. Med.192,953–964.
3. Furie, R., Stohl, W., Ginzler, E., Becker, M., Mishra, N., Chatham, W., Merrill, J. T., Weinstein, A., McCune, J., Zhong, J., et al. (2003). Safety, pharmacokinetics and pharmacodynamic results of a phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum.48(Suppl.), 377 (Abstract).
4. Gobburu, J. V. S., Tenhoor, C., Rogge, M. C., Frazier, D. E., Thomas, D., Benjamin, C., Hess, D. M., and Jusko, W. J. (1998). Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. J. Pharmacol. Exp. Ther.286,925–930.
5. Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005). Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol.174,817–826.